KenH
Well-Known Member
"The Food and Drug Administration (FDA) on Thursday authorized the use of Merck and Ridgeback Biotherapeutics' molnupiravir pill for treating COVID-19, the second such emergency use authorization in two days. ...
Use of molnupiravir in patients under the age of 18 is not authorized because it may affect bone and cartilage growth in that age group. ...
The pill is not recommended for use in pregnant patients. "Based on findings from animal reproduction studies, molnupiravir may cause fetal harm when administered to pregnant individuals," Merck said."
FDA authorizes second COVID-19 antiviral pill, Merck's molnupiravir | Fox Business
Use of molnupiravir in patients under the age of 18 is not authorized because it may affect bone and cartilage growth in that age group. ...
The pill is not recommended for use in pregnant patients. "Based on findings from animal reproduction studies, molnupiravir may cause fetal harm when administered to pregnant individuals," Merck said."
FDA authorizes second COVID-19 antiviral pill, Merck's molnupiravir | Fox Business